Tag: equity
-
Genomics Biotech Raises $40 Million in Venture Funds
Moderna Therapeutics, a biotechnology start-up in Cambridge, Massachusetts developing therapies harnessing messenger RNA, secured some $40 million in venture funding. The financing for this round was led by Flagship Ventures that incubated Moderna Therapeutics, and includes other unamed private investors. The two-year-old company, founded and based on research by scientists at Harvard University and MIT,…
-
U.K. Medical Tech Company Acquires Wound Care Developer
Smith & Nephew, a medical technology company in London, is purchasing Healthpoint Biotherapeutics, a developer of wound treatments in Fort Worth, Texas. In the transaction, Smith & Nephew will acquire all Healthpoint assets for $782 million in cash, with the deal expected to close next month. Olivier Bohuon, Smith & Nephew’s CEO, says the acquisition…
-
Electric Bus Developer Lands $23 Million in Series B Funds
Proterra Inc. in Greenville, South Carolina, a developer of electric buses for public transportation, secured $23 million in series B funds, the second round of venture financing after initial start-up. New investor Hennessey Capital led the round, with new investor NMT Capital, and current investors Kleiner Perkins Caufield & Byers, GM Ventures, Mitsui & Co.…
-
Gene Therapy Biotech Secures $37.5 Million in Venture Funds
Applied Genetic Technologies Corp., a biotechnology company in Gainesville, Florida, gained $37.5 million in series B funds, the second round of financing after initial start-up. Alta Partners and S.R. One Ltd led the financing, with new investor Osage University Partners joining existing investors InterWest, Intersouth Partners, and MedImmune Ventures in the round. Applied Genetic Technologies…
-
Cancer Diagnostics Biotech Lands $13 Million Series B Funds
Epic Sciences Inc., a biotechnology diagnostics developer in San Diego, secured $13 million in series B financing, the second round of venture funding after initial start-up. The funding round includes new investors Domain Associates, Roche Venture Fund, and Pfizer Venture Investments, as well as undisclosed individual participants. Epic Sciences exclusively licensed research by the lab…
-
VC, University Partner on Medical Device Start-Up Company
George Washington University in Washington, D.C., and venture capital company Allied Minds Inc. in Boston, formed LuxCath LLC, a new company that makes a device for increasing the speed and safety of surgery for irregular heartbeat. LuxCath’s technology is based on research by faculty at George Washington’s medical school and engineering department. LuxCath is developing…
-
Takeda Pharma to Acquire Envoy Therapeutics
Takeda Pharmaceuticals, in Osaka, Japan, will acquire the drug discovery company Envoy Therapeutics in Jupiter, Florida for $140 million. Takeda says the merger will mean moving Envoy’s management and scientific staff to Takeda’s San Diego offices after March 2013. Envoy was founded by biophysicist and 2000 Nobel prize winner Paul Greengard, and Rockefeller University colleague…
-
Diagnostics Company Lands $12 Million Series B Funds
Advanced Cell Diagnostics Inc., a genomic diagnostics developer in Hayward, California, secured $12 million in series B funding, the second round of venture financing after initial start up. New Leaf Venture Partners that specializes in health care technology investments led the round, joined by existing investor Morningside Ventures. Advanced Cell Diagnostics makes diagnostic tests that…
-
Life Sciences Can Generate Start-Ups, With a Little Help
A case study of innovation in the life sciences in San Francisco shows academic researchers, with the right kind of support, can generate a high number of start-up companies producing new products for the marketplace. The study focuses on the California Institute for Quantitative Biosciences (QB3) and its entrepreneurial programs, which appears in this week’s…
-
Q3 Venture Funding Drops, Science Sectors Hit Hard
Venture capital (VC) funding for U.S. companies dropped sharply in the third quarter of 2012, with the amount of money invested declining by about a third and number of deals down by almost 10 percent compared to 2011. For the year to date, says Dow Jones VentureSource, a financial industry research service, VC funding totaled…